These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 34546304)

  • 1. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases-Reply.
    Syversen SW; Bolstad N; Haavardsholm EA
    JAMA; 2021 Sep; 326(11):1069-1070. PubMed ID: 34546304
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.
    Syversen SW; Jahnsen J; Haavardsholm EA
    JAMA; 2022 Apr; 327(15):1506-1507. PubMed ID: 35438729
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    Vande Casteele N
    JAMA; 2022 Apr; 327(15):1506. PubMed ID: 35438733
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases.
    Javor E; Hauser G; Skelin M
    JAMA; 2022 Apr; 327(15):1505-1506. PubMed ID: 35438732
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
    Syversen SW; Goll GL; Jørgensen KK; Sandanger Ø; Sexton J; Olsen IC; Gehin JE; Warren DJ; Brun MK; Klaasen RA; Karlsen LN; Noraberg G; Zettel C; Ljoså MKA; Haugen AJ; Njålla RJ; Bruun TJ; Seeberg KA; Michelsen B; Strand EK; Skorpe S; Blomgren IM; Bragnes YH; Dotterud CK; Thune T; Ystrøm CM; Torp R; Mielnik P; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
    JAMA; 2021 May; 325(17):1744-1754. PubMed ID: 33944876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Le Tilly O; Paintaud G; Ternant D
    JAMA; 2021 Sep; 326(11):1069. PubMed ID: 34546307
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Serkland TT; Skrede S; Berg JA
    JAMA; 2021 Sep; 326(11):1068-1069. PubMed ID: 34546308
    [No Abstract]   [Full Text] [Related]  

  • 8. INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE.
    Queiroz NSF; Teixeira FV; Parra RS; Kotze PG
    Arq Gastroenterol; 2020; 57(4):507-510. PubMed ID: 33331484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
    Papamichael K; Dubinsky MC; Cheifetz AS
    JAMA; 2021 Sep; 326(11):1067. PubMed ID: 34546306
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
    Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
    Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1134. PubMed ID: 26427756
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease.
    Ganesananthan S; Durai D
    Clin Med (Lond); 2020 Mar; 20(Suppl 2):s23-s24. PubMed ID: 32409349
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude.
    Loftus EV; Paul S; Roblin X
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2193-2194. PubMed ID: 36610500
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
    Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
    Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.
    Deora V; Kozak J; El-Kalla M; Huynh HQ; El-Matary W
    Acta Paediatr; 2017 Nov; 106(11):1863-1867. PubMed ID: 28779489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease.
    Gil Candel M; Gascón Cánovas JJ; Urbieta Sanz E; Gómez Espín R; Nicolás de Prado I; Iniesta Navalón C
    Rev Esp Enferm Dig; 2020 May; 112(5):360-366. PubMed ID: 32338010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
    Wong U; Cross RK
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
    Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions.
    Srinivas NR
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1133. PubMed ID: 26427755
    [No Abstract]   [Full Text] [Related]  

  • 20. Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Toward Personalized Evidence-Based Dosing Regimens.
    Bourgonje AR; Mian P
    Am J Gastroenterol; 2023 Dec; 118(12):2308-2309. PubMed ID: 38033231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.